NCT06911970 Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment
| NCT ID | NCT06911970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université de Sherbrooke |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2025-04-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine to what extent anticancer immune cells mobilized by aerobic exercise exhibit migratory and functional capacity towards cancer cells in patients undergoing treatment for breast or colorectal cancer. The main questions it aims to answer are: • Do anticancer immune cells mobilized by aerobic exercise will display migratory and functional capacity in patients undergoing treatment for curable breast or colorectal cancer? Hypothesis: exercise will promote cell migration and these cells will display anti-cancer functional characteristics, suggesting a possible adjuvant and immunotherapeutic use of exercise. • Do the magnitude of this anti-cancer immune response to exercise depend on the intensity of exercise? Hypothesis: the achievement of a higher intensity of effort will enable greater mobilization of the cytotoxic lymphocytes of interest, but also the expression of markers predicting a more interesting adjuvant potential to immunotherapy. Researchers will compare the effect of two exercise sessions, one moderate-intensity continuous exercise session (MOD) and one high-intensity interval exercise (HIIE) on the migration and anticancer potentials of mobilized immune cells. Individuals aged between 40 and 70 with curable colon or breast cancer will be recruited to carry out a cross-over study with two experimental conditions. After a preliminary assessment visit, they will take part in: * Two familiarization visits to validate the exercise prescription * Two experimental visits (HIIE and MOD). During these conditions, blood samples will be taken before, after and 1 hour after the end of exercise to collect immune cells in the blood. At the end of the visits, participants will leave with an accelerometer to wear for three days depending on conditions, and a notebook containing a questionnaire to assess fatigue levels over the same three days.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of non-metastatic breast or colon cancer * Age between 40 and 70 * Have started chemotherapy or immunotherapy treatment and have at least three treatments remaining in the cycle * ECOG stage 0 to 1 * Be able to perform moderate-intensity aerobic exercise (MOD) or EPI type cycling according to the established prescription and without experiencing pain in connection with the bicycle saddle Exclusion Criteria: * Orthopedic, cardiac or metabolic limitation preventing safe aerobic exercise * Non-controlled health condition * Use of beta-blockers * Planned surgery during the study period.
Contact & Investigator
Eléonor Riesco, PhD
PRINCIPAL INVESTIGATOR
University of Sherbrooke, Faculty of Physical Activity Sciences, Department of Kinanthropology
Frequently Asked Questions
Who can join the NCT06911970 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06911970 currently recruiting?
Yes, NCT06911970 is actively recruiting participants. Contact the research team at eleonor.riesco@usherbrooke.ca for enrollment information.
Where is the NCT06911970 trial being conducted?
This trial is being conducted at Sherbrooke, Canada, Sherbrooke, Canada.
Who is sponsoring the NCT06911970 clinical trial?
NCT06911970 is sponsored by Université de Sherbrooke. The principal investigator is Eléonor Riesco, PhD at University of Sherbrooke, Faculty of Physical Activity Sciences, Department of Kinanthropology. The trial plans to enroll 44 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.